Sales and Marketing

The antidepressant fluvoxamine could treat COVID-19 patients and stop their symptoms from worsening, according to a new study. 

The British Prime Minister Boris Johnson has begun working in self isolation after coming into contact with an MP who …

Professor Guido Rasi, Executive Director at the European Medicines Agency (EMA), serves his final day at the European regulator today, …

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

With the news that Pfizer and BioNTech’s COVID-19 vaccine candidate demonstrated 90% efficacy in a Phase 3 interim analysis, it …

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

The Scottish Medicines Consortium has approved Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are …

AstraZeneca has committed to an agreement to deliver 22 million doses of its COVID-19 vaccine candidate, co-developed in partnership with …

AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …

Kate Bingham, the head of the British Government’s vaccine taskforce, faces scrutiny after it was revealed her venture capital firm …

The FDA has authorised the marketing of Nightware, a digital therapeutic application for the Apple Watch, in treating sleep disturbances.  …

Viiv Healthcare’s cabotegravir is more effective in preventing HIV in women than the oral standard of care, according to an …

China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …